Compare · AMLX vs NVO
AMLX vs NVO
Side-by-side comparison of Amylyx Pharmaceuticals Inc. (AMLX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMLX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $211.73B, about 116.3x AMLX ($1.82B).
- Over the past year, AMLX is up 155.5% and NVO is down 33.0% - AMLX leads by 188.5 points.
- AMLX has been more active in the news (8 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 24 for AMLX).
- Company
- Amylyx Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $16.38+0.74%
- $47.40+3.29%
- Market cap
- $1.82B
- $211.73B
- 1M return
- +17.67%
- +6.83%
- 1Y return
- +155.54%
- -32.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 8
- 3
- Recent ratings
- 24
- 25
Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AMLX
- Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
- SEC Form 4 filed by Director Firestone Karen
- SEC Form 4 filed by Director Zeiher Bernhardt G
- SEC Form 4 filed by Director Milne George M Jr
- SEC Form 4 filed by Director Quimi Daphne
- SEC Form 4 filed by Director Fonteyne Paul R.
- Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
- SEC Form 8-K filed by Amylyx Pharmaceuticals Inc.
- Director Firestone Karen bought $51,338 worth of shares (3,800 units at $13.51), increasing direct ownership by 6% to 66,900 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S